
## Yeshin Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4618645/publications.pdf Version: 2024-02-01



YESHIN KIM

#	Article	IF	CITATIONS
1	Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease. Brain, 2019, 142, 1093-1107.	3.7	164
2	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using <sup>18</sup> F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	4.5	85
3	Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. Scientific Reports, 2017, 7, 9541.	1.6	39
4	Machine Learning-based Individual Assessment of Cortical Atrophy Pattern in Alzheimer's Disease Spectrum: Development of the Classifier and Longitudinal Evaluation. Scientific Reports, 2018, 8, 4161.	1.6	39
5	A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 681-691.	1.2	38
6	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.4	35
7	Clinical significance of amyloid $\hat{l}^2$ positivity in patients with probable cerebral amyloid angiopathy markers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1287-1298.	3.3	31
8	Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2368-2376.	3.3	30
9	Prognostic value of amyloid PET scan in normal pressure hydrocephalus. Journal of Neurology, 2018, 265, 63-73.	1.8	28
10	A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1938-1948.	3.3	23
11	Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. NeuroImage: Clinical, 2019, 24, 101941.	1.4	21
12	Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Scientific Reports, 2019, 9, 1814.	1.6	21
13	Trajectories of Physiological Brain Aging and Related Factors in People Aged from 20 to over-80. Journal of Alzheimer's Disease, 2018, 65, 1237-1246.	1.2	17
14	Sex-specific relationship of cardiometabolic syndrome with lower cortical thickness. Neurology, 2019, 93, e1045-e1057.	1.5	16
15	Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 292-303.	3.3	15
16	Cortical atrophy pattern–based subtyping predicts prognosis of amnestic MCI: an individual-level analysis. Neurobiology of Aging, 2019, 74, 38-45.	1.5	13
17	Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1971-1983.	3.3	13
18	Depressive symptoms are associated with worse cognitive prognosis in patients with newly diagnosed idiopathic Parkinson disease. Psychogeriatrics, 2020, 20, 880-890.	0.6	13

**Үезні** Кім

#	Article	IF	CITATIONS
19	Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions. Journal of Alzheimer's Disease, 2020, 76, 281-290.	1.2	13
20	Distinctive Clinical Effects of Haemorrhagic Markers in Cerebral Amyloid Angiopathy. Scientific Reports, 2017, 7, 15984.	1.6	12
21	Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea. Yonsei Medical Journal, 2017, 58, 1055.	0.9	12
22	The Impact of APOE ɛ4 in Alzheimer's Disease Differs According to Age. Journal of Alzheimer's Disease, 2018, 61, 1377-1385.	1.2	12
23	Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET. Alzheimer's Research and Therapy, 2020, 12, 6.	3.0	12
24	Disease progression modeling of Alzheimer's disease according to education level. Scientific Reports, 2020, 10, 16808.	1.6	12
25	The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Journal of Alzheimer's Disease, 2020, 78, 573-585.	1.2	10
26	Association of Nutritional Status with Cognitive Stage in the Elderly Korean Population: The Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease. Journal of Clinical		

Yeshin Kim

#	Article	IF	CITATIONS
37	An Evaluation of Machine Learning Classifiers for Prediction of Alzheimer's Disease, Mild Cognitive Impairment and Normal Cognition. , 2021, , .		3
38	Dynamic association between AT(N) profile and cognition mediated by cortical thickness in Alzheimer's continuum. NeuroImage: Clinical, 2020, 27, 102282.	1.4	2
39	A Case of Squamous Cell Lung Cancer Representing as Guillain-Barre Syndrome Associated with Monospecific Anti-GD1b IgG. Korean Journal of Clinical Neurophysiology, 2015, 17, 31.	0.1	0
40	P1-409: Detrimental Effects of Coronary Artery Calcification Scores on Cortical Thickness Associated with Patterns of The Default Mode Network in Cognitively Normal Individuals. , 2016, 12, P590-P591.		0
41	[P1–224]: <sup>18</sup> Fâ€AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.4	0
42	[P2–406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING <sup>18</sup> Fâ€THK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.4	0
43	[P2–407]: PREVALENCE OF AMYLOIDâ€PET POSITIVITY ACCORDING TO AGE AND <i>APOE</i> GENOTYPE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P787.	0.4	0
44	[P2–424]: PROTECTIVE EFFECTS OF EDUCATION ON THKâ€5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT W SUSPECTED NONâ€ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	/ITH 0.4	0
45	[P3–194]: DIAGONAL EARLOBE CREASE, CEREBRAL SMALL VESSEL DISEASE, AND BETAâ€AMYLOIDOSIS IN COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P1009.	0.4	0
46	[P3–258]: TRAJECTORIES OF COGNITIVE DECLINE IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1042.	0.4	0
47	[P3–413]: CLINICAL EFFECT OF SMALLâ€VESSEL DISEASE AND WHITE MATTER NETWORK ON DEPRESSION IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1124.	0.4	0
48	[P4–169]: COGNITIVE TRAJECTORIES IN PATIENTS WITH NONâ€AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2017, 13, P1326.	0.4	0
49	[P1–423]: THE DEVELOPMENT OF AN ALZHEIMER'S DISEASE RISK SCORE BASED ON THE CORTICAL THICKNESS ANALYSES. Alzheimer's and Dementia, 2017, 13, P440.	5 <sub>0.4</sub>	0
50	[P1–428]: NONâ€ALCOHOLIC FATTY LIVER DISEASE AND CEREBRAL SMALLâ€VESSEL DISEASE IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P443.	′ 0.4	0
51	[P1–454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€5351 UPTAKES IN PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.4	0
52	[P2–318]: RISK SCORE FOR THE PREDICTION OF DEMENTIA RISK IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL, MULTI ENTER CLINICâ€BASED STUDY. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
53	[O4–O4–O3]: SYNERGISTIC EFFECT OF TAU, AMYLOID, AND VASCULAR BURDEN ON COGNITIVE DECLINE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2017, 13, P1235.	0.4	0
54	Myoclonic status epilepticus in hypoxic ischemic encephalopathy which recurred after somatosensory evoked potential testing. Annals of Clinical Neurophysiology, 2017, 19, 136.	0.1	0

**Үезні** Кім

#	Article	IF	CITATIONS
55	P1â€382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.4	0
56	P2â€469: THE BRAIN DONATION PROGRAM IN SOUTH KOREA. Alzheimer's and Dementia, 2018, 14, P902.	0.4	0
57	P4â€096: REPLICATING VISUAL ASSESSMENTS OF <sup>18</sup> Fâ€FLORBETABEN PET USING MACHINE LEARN TECHNIQUE. Alzheimer's and Dementia, 2018, 14, P1473.	ING 0.4	0
58	O1â€14â€01: PULMONARY FUNCTION AND CEREBRAL SMALL VESSEL DISEASE AND CORTICAL THINNING IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P256.	0.4	0
59	P2â€319: DISEASE COURSE MODELING OF ALZHEIMER'S DISEASE DEPENDING ON AMYLOID DEPOSITION: AN ACCELERATED LONGITUDINAL DESIGN. Alzheimer's and Dementia, 2018, 14, P804.	0.4	0
60	ICâ€Pâ€121: EFFECTS OF CARDIOMETABOLIC RISK FACTORS ON BRAIN AGING IN THE ELDERLY. Alzheimer's and Dementia, 2018, 14, P102.	0.4	0
61	P1â€407: ALZHEIMER'S DISEASE WITH RIGHT FOCAL CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P459.	0.4	0
62	ICâ€Pâ€014: REPLICATING VISUAL ASSESSMENTS OF <sup>18</sup> Fâ€FLORBETABEN PET USING MACHINE LEA TECHNIQUE. Alzheimer's and Dementia, 2018, 14, P22.	ARNING	0
63	P3â€393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT Alzheimer's and Dementia, 2018, 14, P1248.	Г. <sub>0.4</sub>	0
64	P1â€483: COGNITIVE RESERVE AND EFFICIENCY NETWORK: IN NORMAL COGNITION, AMNESTIC MCI AND ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P511.	0.4	0
65	P3â€346: CLINICAL SIGNIFICANCE OF AMYLOID BETA POSITIVITY IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY MARKERS. Alzheimer's and Dementia, 2018, 14, P1216.	0.4	0
66	ICâ€Pâ€050: AMYLOID DEPOSITION IN THE SUBCORTICAL REGION PREDICTS COGNITIVE DECLINE. Alzheimer's an Dementia, 2018, 14, P49.	nd 0.4	0
67	P3â€425: ALZHEIMER'S DEMENTIA CONVERSION IN AMNESTIC MCI ACCORDING TO NEUROPSYCHOLOGICAL PROFILE. Alzheimer's and Dementia, 2018, 14, P1272.	0.4	0
68	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 69, 213-225.	1.2	0
69	Two cases of non-fluent variant primary progressive aphasia with different pathological diagnoses. Precision and Future Medicine, 2021, 5, 142-148.	0.5	0
70	Clinical outcomes of increased regional amyloid uptake in patients with subthreshold global amyloid levels. Alzheimer's and Dementia, 2021, 17, .	0.4	0